A cryogenic storage risk assessment is the structured evaluation of every way a cryogenic storage facility could put its samples at risk — from a missed LN₂ delivery to the loss of an entire site. The most established tool for the job is FMEA (failure mode and effects analysis), which rates each potential failure by severity, likelihood and detectability, making very different risks comparable.
Consarctic® calls this discipline cryogenic risk engineering: the systematic identification, evaluation and design-out of failure modes in cryogenic storage. The aim is not to bury every conceivable risk under hardware. It is to put the right safeguards in place first.
Redundancy, alarms and backup power are well documented. The question that comes first is how to decide, methodically, which of them a facility actually needs.
Intuition misjudges risk in a predictable way: rare, catastrophic events are underestimated and frequent, harmless disruptions overestimated. A team that has not seen a vacuum failure in fifteen years assumes one is unlikely. A team that acknowledges a false alarm every week starts to see the alarms as the problem.
The result is budget spent on comfort rather than protection. A facility that has eliminated nuisance alarms but keeps its irreplaceable samples at a single site feels safer — and is more exposed.
A structured assessment replaces memory with evaluation, including for scenarios that have never happened but would decide whether a holding is lost entirely.
FMEA breaks a system down into potential failure modes and rates each on three scales from 1 to 10: severity (S) of the effect, occurrence (O) of the cause and detection (D), meaning how reliably the failure is caught before harm is done. For detection, 1 means almost certain and 10 practically impossible.
Traditionally, the three ratings are multiplied into a risk priority number: RPN = S × O × D, giving a range from 1 to 1,000.
The RPN has a well-known weakness. A severity-10 failure with good detection can score lower than a frequent, harmless nuisance. The harmonised AIAG & VDA FMEA Handbook, published in 2019, therefore replaced the RPN with Action Priority (AP), which evaluates combinations in a fixed order of importance: severity first, then occurrence, then detection.
In GMP environments, the framework is ICH Q9(R1) on quality risk management (2023). It expects effort, formality and documentation to be commensurate with the level of risk, and the revision explicitly addresses subjectivity in risk assessment. A research lab with one tank of replaceable material can therefore work with a lean, well-reasoned analysis. A GMP cell bank needs the full depth.
These form the backbone of the analysis in most LN₂ facilities, each broken down into cause, effect, detection and mitigation.
Every safeguard acts on a specific factor. Monitoring and escalation improve detection, automated refilling reduces occurrence, and redundancy through a second vessel or site reduces the effective severity. Once you know which factor is driving a risk, you know which safeguard will move it.
Physics adds a further advantage: an LN₂ tank has no compressor to fail, and its thermal inertia buys response time. The BSF420+, for instance, has a datasheet static evaporation rate of 8.3 litres per day at a capacity of 464 litres; routine openings raise consumption.
These ratings are an illustrative example only; every facility must define and justify its own scales. The scenario: a vessel of clinical stem cell products, refilled manually, with only a local alarm on the unit.
Step 1 is revealing: a poorly closed lid rated S = 4, O = 6, D = 5 also scores an RPN of 120, so on RPN alone both look equally urgent. Action Priority keeps the severity-10 failure rated high — and rightly so.
A risk assessment is only valid for the facility it describes, so it needs to be reviewed:
Findings belong in SOPs, training content and requalification, and occurrence ratings should increasingly rest on your own operating data rather than estimates. That cycle of assessment, action and review is what turns a one-off exercise into cryogenic risk engineering.
Consarctic GmbH has a concrete technical answer for each FMEA factor. Our standard is "Zero-Compromise Cryo Safety": no high-severity failure mode is left without a justified safeguard.
Installation and IQ/OQ/PQ qualification are carried out by certified technicians. Consarctic GmbH brings decades of experience, is certified to EN ISO 13485:2016 and ISO 9001:2015, manufactures all systems to GMP-compliant standards and serves customers in more than 30 countries. We share responsibility with you for the safety of your most critical samples.
Organisations including Charité Universitätsmedizin Berlin, Hamad Medical Corporation, Roche, GSK and Qatar Biobank rely on cryogenic technology from Consarctic®.
An FMEA (failure mode and effects analysis) for cryogenic storage rates every potential failure mode — such as an interrupted LN₂ supply, a faulty level sensor or the loss of a site — for severity, occurrence and detection on scales from 1 to 10. The result is a ranked list showing which safeguards should be implemented first.
The highest level of safety comes from a coordinated system rather than any single tank. Consarctic® combines BSD+ and BSF+ series stainless steel cryogenic tanks with the Consarctic® Monitoring System and Biolog®, automated LN₂ supply via FMCS Touch and NRT3010, and planned redundancy with a second vessel or site. IQ/OQ/PQ qualification by certified technicians and a 24/7 emergency service keep the whole system secure in operation.
Validation applies to the backup concept of a specific installation, not to a product. With Consarctic®, that concept starts from a physical advantage: the cryogenic tanks themselves need no power. IQ/OQ/PQ qualification demonstrates that monitoring, alarming and automatic refilling operate as specified; ASR+ dry shippers provide emergency transfer capacity, and the Consarctic GmbH 24/7 emergency service delivers on-site support within hours, 365 days a year.
It should be reviewed after every change to the facility under change control, after every incident or near miss, and at defined intervals, for example annually. The findings should feed into SOPs, training and requalification.
No cryogenic facility can reduce every risk to zero. A sound risk assessment makes sure budget and engineering go first to where a failure would cost irreplaceable samples — with the reasoning documented.
Reviewing the risks in your cryogenic storage, or planning a new facility? Consarctic GmbH plans, supplies, qualifies and supports cryogenic storage infrastructure for critical samples — one accountable partner from first concept to a running, GMP-validated facility. Get in touch.